Skip to content
PaperFren

Circadian biology

CK1ε, PERIOD2, and cancer-selective growth arrest

Yang WS, Stockwell BR · Genome biology · 2008

Open access · cc by · source: Europe PMC

Cancer cells depend more than normal cells on casein kinase 1-epsilon; inhibiting CK1ε causes PERIOD2-dependent growth arrest.

Study at a glance

Design
Animal / in-vitro — Kinase shRNA library screen and CK1ε inhibitor assays in isogenic cancer vs normal cells
N
Library targets 1,006 genes; cell-line dependency study — no single sample N
Population
Isogenic cancer and normal cell models
Outcome
Cancer-selective, PERIOD2-dependent growth arrest after CSNK1E/CK1ε inhibition

Structured fields used in claim comparison tables when every cited study has a complete layer.

Key findings

CSNK1E is a cancer-preferential dependency; CK1ε inhibitors phenocopy shRNA, and growth arrest is PERIOD2-dependent.

Methodology

Authors used shRNA and kinase-inhibitor perturbations across isogenic cancer vs normal cell models to find selective dependencies, focusing on CSNK1E/CK1ε and PERIOD2.

Limitations

Not a patient clinical trial of CK1ε drugs; selectivity and potency still need medicinal chemistry.

How this study connects

Role on claims

Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.

  • SupportsCircadian biologyconcept

    Multiple empirical papers in this library examine circadian biology with mechanistic biological findings.

    Evidence for the claim as stated.

  • SupportsCircadian biologyconcept

    CSNK1E is a cancer-preferential dependency; CK1ε inhibitors phenocopy shRNA, and growth arrest is PERIOD2-dependent.

    Evidence for the claim as stated.

  • SupportsCircadian biologyconcept

    Systems and scales differ across circadian biology studies (species, tissues, methods), so mechanisms should not be over-generalised.

    Evidence for the claim as stated.

  • CSNK1E/CK1ε was a cancer-preferential dependency: shRNA and kinase inhibitors phenocopied each other, and growth arrest was PERIOD2-dependent in isogenic cancer versus normal models. That is a selective-dependency result, not a patient trial of CK1ε drugs.

    Evidence for the claim as stated.

  • Loss-of-function tools are not interchangeable. CK1ε used shRNA plus inhibitors in mammalian cancer models; USP8 used Drosophila RNAi; IFN work used receptor knockouts and siRNA in macrophages; PDLP used plant combined KOs. A 'knockdown paper' in flies is not the same genetic lesion as a mouse IFNAR1 knockout or an Arabidopsis double mutant.

    Evidence for the claim as stated.

Open questions

Tensions this paper is part of

From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.

Related papers in this topic

Same topic cluster — not a recommendation engine.